A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease
Published inNuclear Medicine Communications, vol. 41, no. 9, p. 837-840
Publication date2020
Research group
Citation (ISO format)
SHIRI LORD, Isaac et al. A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease. In: Nuclear Medicine Communications, 2020, vol. 41, n° 9, p. 837–840. doi: 10.1097/MNM.0000000000001269
Main files (1)
Article (Published version)
Identifiers
- PID : unige:142492
- DOI : 10.1097/MNM.0000000000001269
- PMID : 32796470
Commercial URLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485524/
ISSN of the journal0143-3636
